Get the content you want anytime you want.

The Contagion® Healthcare Associated Infections (HAI) specialty page provides HAI-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


MGB Biopharma Announces Successful Phase 2 C. difficile Candidate Trial
A dosage of 250 mg twice daily for 10 days was confirmed for the next phase of trials after achieving initial and sustained cure in 100% of patients.
Q&A: Assessing RBX2660 for Recurrent <i>C difficile</i>
An interview with the Rebiotix founder on the microbiota-based therapy and the newest preliminary pivotal phase 3 findings.
Stronger Trials Needed to Understand FMT Risks, Benefits
Before undergoing fecal microbiota transplant, “patients deserve risk mitigation, which can be accomplished with thorough vetting and regulation,” the authors of a new paper wrote.
Incidence of Hospital-Acquired C Diff Declines, But Challenges Remain: Public Health Watch
Community-acquired infections—including those associated with outpatient settings—are still problematic, authors say.
Real World Bezlotoxumab Use for Recurrent <i>C diff</i>
After the MODIFY trial, investigators wanted to explore how bezlotoxumab treated patients in the real world.
First English FMT Bank Sees High Clinical Response Rate
Results from England’s first licensed FMT stool bank are now available.
Electronic Alerts Aid in <i>C diff</i> Diagnostic Stewardship
An electronic alert that aids in diagnostic stewardship may be helpful in reducing inappropriate testing for C diff, according to a new study.  
Can Enteral Vancomycin <i>C Diff</i> Prophylaxis Improve Outcomes in HSCT Recipients?
Using enteral vancomycin for C diff prophylaxis may be the key to reducing morbidity and improving outcomes in pediatric and young adult recipients of HSCT.
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?